LGK-974 is under clinical development by Novartis and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas.

NG-350a is under clinical development by Akamis Bio and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas.

“The FDA approval of Bizengri marks an important milestone for patients with pancreatic adenocarcinoma or NSCLC that is advanced unresectable or metastatic and harbors the NRG1 gene fusio ...

or metastatic pancreatic adenocarcinoma harboring a NRG1 gene fusion with disease progression on or after prior systemic therapy. The efficacy of Bizengri was determined in the eNRGy study of 64 ...

Key eligibility criteria were patients age 18 years or older and had undergone complete macroscopic resection for ductal adenocarcinoma of the pancreas. Country of participation and resection margin ...

Pancreatic ductal adenocarcinoma (“PDAC”) accounts ... Other less common metastatic sites are the lungs, brain, kidney, and bone. In its early stages, pancreatic cancer does not typically ...

Pancreatic ductal adenocarcinoma (“PDAC”) accounts for more than 90% of all pancreatic tumors. It can be located either in the head of the pancreas or in the ody/tail. Pancreatic cancer usually ...

Pancreatic ductal adenocarcinoma (“PDAC”) accounts for more than 90% of all pancreatic tumors. It can be located either in the head of the pancreas or in the body/tail.

Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year Survival Rate and 37% ...

Improved imaging methods are crucial to map pancreatic ductal adenocarcinoma (PDAC ... an imaging agent to track claudin-4 in primary and metastatic PDAC tumours.

Design In a large retrospective cohort study involving 110 patients with pancreatic ductal adenocarcinoma (PDAC), we assessed the density of CD68-TAM immune reactive area (%IRA) at the tumour–stroma ...